When the brand name is the health claim: the ASA on GuLP-1
A May ruling held that a weight-loss supplement's own name would be read as a health claim the advertiser could not show was authorised — and that an injection-pen comparison table put it in the territory of prescription medicines.
Most advertising rulings in this category turn on a sentence. This one turned on a word.
On 6 May 2026 the Advertising Standards Authority ruled on a complaint against GLP-1 Pro Ltd, trading as GuLP-1, under reference A25-1317723. Three issues were investigated; two were upheld, and the third was informally resolved after the advertiser agreed to amend its advertising. The finding worth sitting with is the first of the two upheld: the ASA held that the product’s name, stylised as “GuLP-1”, would itself be understood as a specific health claim — that the product could affect GLP-1 production.
What the ruling records
Per the ruling, phrases including “Stubborn weight gone”, “Natural weight loss” and “Digestive: Increase GLP-1 naturally” were specific health claims, and the ASA said it had seen no evidence that they were authorised on the Great Britain nutrition and health claims Register in relation to the product or any of its ingredients. Rules 15.1, 15.1.1 and 15.7 were breached. The same test, applied to the brand name, produced the same answer.
The second upheld issue turned on wording and presentation together. The homepage referred to “sustainable weight loss without injections” and carried a comparison table alongside an image of an injection pen; the ASA determined consumers were likely to understand that as meaning the product was equivalent to, or had similar effects to, GLP-1 agonist injections, which are prescription-only medicines. It treated “Stop Your Cravings” and “Natural Alternative To Trending Weight Loss Products” as medicinal claims in that context. Rules 12.1, 12.11, 15.6 and 15.6.2 were breached on that point.
Why the name finding is the interesting one
A brand name tends to be treated as decoration — the thing above the claims rather than one of them. This ruling declines that distinction. A name that spells out a mechanism is communicating the mechanism, and putting it in a logo does not move it outside the rules.
Naming has been quietly absorbing work that copy could no longer do, and the pattern is one we have written about before: borrow the vocabulary of a drug class, and let the reader complete the sentence. The ASA’s position is that the reader completing it is the point, and therefore the advertiser’s responsibility.
Two things this ruling is not. It is not a finding about whether the product does anything — the register question is about authorisation, not about a trial. And it is not a statement that anything has been banned or withdrawn; the published ruling says what it says and no more.
Nothing sold as a food supplement has been evaluated by the Food and Drug Administration, and nothing in this category is intended to diagnose, treat, cure or prevent any disease. Where a prescribed medicine is genuinely part of somebody’s life, the person to raise it with is the clinician who prescribed it, and never a comparison table.